Tuesday, 4 June 2013

The Mystery About Cyanide Taste


What is potassium cyanide??
A chemical compound with the chemical formula KCN is commonly known as the Potassium cyanide. This is a colorless crystalline compound, highly soluble in water and is similar in appearance as that of sugar. Potassium cyanide is considered to be highly toxic in nature. Potassium cyanide is considered to be one of the most deadly compounds being discovered till date.

Production of Potassium Cyanide:
Potassium Cyanide can be produced mainly by treating hydrogen cyanide in the presence of a fifty percent of an aqueous solution of potassium hydroxide. After that the aqueous solution is either evaporated in a vacuum or by treating the form amide in the presence of potassium hydroxide. On an average per year approximately fifty thousand tons of potassium cyanide are being produced all over the world.
Use of Potassium Cyanide:
Potassium Cyanide is mainly used for the purpose of electroplating, organic synthesis of a number of chemical compounds, gold mining and so on. In accordance with the large scale use of Potassium Cyanide, it is also used in smaller scale applications like in the jewelry manufacturing industry for chemical buffing and gliding. Other than those mentioned earlier, Potassium Cyanide is also used by the entomologists as it is an excellent killing agent, and it has the unique capability of causing minimum damage to the highly fragile specimens.
Mystery about Potassium Cyanide:
Since, the time of its invention, the biggest mystery that has been surrounded with Potassium Cyanide, is about the taste of it. Due to the fact that Potassium Cyanide is exceedingly poisonous substance and can cause death of a person in seconds, the taste of it has remained a mystery or a fact yet to be known to the world. Though, many researches and tests have been conducted to find the taste of Potassium Cyanide but none of them could come up with the appropriate result.
Different views about the taste of Potassium Cyanide:
There has been number of views among the scientists about the taste of the Potassium Cyanide, some of them are as follows:
· Since on hydrolysis of KCN, the resultant compound that are formed are KOH and HCN, which are strong base and weak base respectively, Potassium Cyanide is confirmed to be basic nature. Since at room temperature HCN is a gas which evolves and the solution is expected to have more KOH, so the taste of Potassium Cyanide is assumed to be bitter.
· Some, scientists who have died while finding the taste of Potassium cyanide, could only write the alphabet “S” before dying, so it is not conclusive whether it is sour, sweet or salty in taste.
Conclusion:
Though, a huge number of scientists sacrificed their lives in order to find the taste of Potassium cyanide, but it remained a mystery for long, until and unless a goldsmith from India named MP Prasad in an attempt to commit suicide with the help of Potassium cyanide could finally reveal the taste of Potassium cyanide. As per the suicide note of him the taste of Potassium Cyanide is very much acrid, that is irritatingly harsh and sharp. This fact about the taste of Potassium cyanide is approved by the World Health Organization and is marked as an extraordinary discovery in the field of science.

Are Biodegradable Heart Stents Safe?


A breakthrough has been achieved in the stream of medical science. An alternative to the metallic stent has been found and is called biodegradable or bio-absorbable stents.


Difference between the two
Metallic stents which are in use for a long time now, had some disadvantages. These stents helps to keep the blocked arteries open to enable the flow of oxygen and blood, but also causes retenosis, that is, it scars up vessel tissue causing the arteries to clog again. Even though drug infused metallic stents have also been used as an alternative, it still does not lower the risks of other complications.
Biodegradable stents, on the other hand causes no such complications. It opens up the blocked arteries and dissolves itself after fulfilling its task, thus, minimizing the occurrence of any complication. It is made up of poly-l-lactide, a naturally dissolving material. It is said to dissolve in a time span of 18 months to three years. Another advantage of this stent is that it does not prevent the detection of other blockages as opposed to the metallic stents which would refract the rays of the scan, making it hard for detection.
Benefits of not having a permanent stent
One of the greatest benefits of not having a permanent stent is that it allows the lumen to expand. When a permanent metallic stent is used it does not allow the lumen to grow, thus hindering remodeling even though it allows the vessel around the stent to develop.
Another benefit is they do not produce any kind of inflammatory reactions as opposed to metallic stents.
How does a biodegradable stent work?
Arteries start getting clogged up due to the accumulation of fatty matter like chlorestol on the inner wall of the arteries that are responsible for providing blood to the heart. As it advances, it reduces the width of the lumen in return diminishing the amount of blood flowing into the heart. This is when a person undergoes a chest pain known as angina.
This disease can be arrested at the initial stage with the help of medication. But a person suffers a heart attack when the precautions are not taken, or when the artery is fully obstructed. That is when the surgical procedure of angioplasty is done. In angioplasty, a balloon is introduced into the artery through a guide wire and is inflated where the blockage is located. After this the stent is introduced so that it keeps the artery open.
The biodegradable stent releases a drug called everolimus which prevents irregular tissue growth.
Researches and studies that classify biodegradable as safe
Kunhiko Kosuga, who has a MD, PhD and is also the director of cardiology at Shiga Medical Center for Adults in Moriyana City, Japan, did a research on these new stents. He and his fellow researchers studied 44 men and 6 women who had undergone angioplasty and had used biodegradable stents to open up the affected arteries. They looked for various complications like clots, deaths, and other causes. The result is as follows:
◦ for the deaths associated with heart diseases, the survival rate was 98%.
◦ for death from all causes, the survival rate was 87%.
◦ there was no main cardiac problems in half the patients.
◦ Only four patients suffered heart attacks.
◦ The blood vessel involved had re-narrowed in 16% of the patients, in one year after undergoing the procedure.
◦ there were two clots that were found within the stent. One was due to the drug-infused stent close to the biodegradable one.
Countries who welcomed biodegradable stents
Nine European countries, Middle East, parts of Latin America and parts of Asia like India, Hong Kong, Philippines and Vietnam are already using these stents. In Europe, Asia-Pacific, Canada and Latin America, over 600 patients have taken part in the trial which aspires to have 1000 patients from over 100 centres present in these counties. Even Singapore has approved of these stents from 20th December, 2012.
However, doctors are still awaiting results for the long term effects on the patients
Even though the cost for manufacturing these stents is very expensive, doctors worldwide are optimistic that they will replace metallic stents eventually.
About The Author: Alia is a writer/blogger by profession. She loves writing, travelling and reading books. She contributes to Hydroxycut
Courtesy: Alia and http://www.biotechblog.org/

Life-Producing Phosphorus Carried to Earth by Meteorites


June 4, 2013 — Scientists may not know for certain whether life exists in outer space, but new research from a team of scientists led by a University of South Florida astrobiologist now shows that one key element that produced life on Earth was carried here on meteorites.


In an article published in the new edition of the Proceedings of the National Academy of Sciences, USF Assistant Professor of Geology Matthew Pasek and researchers from the University of Washington and the Edinburg Centre for Carbon Innovation, revealed new findings that explain how the reactive phosphorus that was an essential component for creating the earliest life forms came to Earth.
The scientists found that during the Hadean and Archean eons -- the first of the four principal eons of Earth's earliest history -- the heavy bombardment of meteorites provided reactive phosphorus that when released in water could be incorporated into prebiotic molecules. The scientists documented the phosphorus in early Archean limestone, showing it was abundant some 3.5 billion years ago.
The scientists concluded that the meteorites delivered phosphorus in minerals that are not seen on the surface of Earth, and these minerals corroded in water to release phosphorus in a form seen only on the early Earth.
The discovery answers one of the key questions for scientist trying to unlock the processes that gave rise to early life forms: Why don't we see new life forms today?
"Meteorite phosphorus may have been a fuel that provided the energy and phosphorus necessary for the onset of life," said Pasek, who studies the chemical composition of space and how it might have contributed to the origins of life. "If this meteoritic phosphorus is added to simple organic compounds, it can generate phosphorus biomolecules identical to those seen in life today."
Pasek said the research provides a plausible answer: The conditions under which life arose on Earth billions of years ago are no longer present today.
"The present research shows that this is indeed the case: Phosphorus chemistry on the early Earth was substantially different billions of years ago than it is today," he added.
The research team reached their conclusion after examining Earth core samples from Australia, Zimbabwe, West Virginia, Wyoming and in Avon Park, Florida.
Previous research had showed that before the emergence of modern DNA-RNA-protein life that is known today, the earliest biological forms evolved from RNA alone. What has stumped scientists, however, was understanding how those early RNA-based life forms synthesized environmental phosphorus, which in its current form is relatively insoluble and unreactive.
Meteorites would have provided reactive phosphorus in the form of the iron-nickel phosphide mineral schreibersite, which in water released soluble and reactive phosphite. Phosphite is the salt scientists believe could have been incorporated into prebiotic molecules.
Of all of the samples analyzed, only the oldest, the Coonterunah carbonate samples from the early Archean of Australia, showed the presence of phosphite, Other natural sources of phosphite include lightning strikes, geothermal fluidsand possibly microbial activity under extremely anaerobic condition, but no other terrestrial sources of phosphite have been identified and none could have produced the quantities of phosphite needed to be dissolved in early Earth oceans that gave rise to life, the researchers concluded.
The scientists said meteorite phosphite would have been abundant enough to adjust the chemistry of the oceans, with its chemical signature later becoming trapped in marine carbonate where it was preserved.
It is still possible, the researchers noted, that other natural sources of phosphite could be identified, such as in hydrothermal systems. While that might lead to reducing the total meteoric mass necessary to provide enough phosphite, the researchers said more work would need to be done to determine the exact contribution of separate sources to what they are certain was an essential ingredient to early life.

Genetic Editing Shows Promise in Duchenne Muscular Dystrophy


June 4, 2013 — Using a novel genetic 'editing' technique, Duke University biomedical engineers have been able to repair a defect responsible for one of the most common inherited disorders, Duchenne muscular dystrophy, in cell samples from Duchenne patients.


Instead of the common gene therapy approach of adding new genetic material to "override" the faulty gene, the Duke scientists have developed a way to change the existing mutated gene responsible for the disorder into a normally functioning gene. The Duke researchers believe their approach could be safer and more stable than current methods of gene therapy.
The researchers are now conducting further tests of this new approach in animal models of the disease.
Duchenne muscular dystrophy is a genetic disease affecting one in 3,600 newborn males. The genetic mutation is found on the X chromosome, of which males have only one copy. (Females, with two X chromosomes, presumably have at least one good copy of the gene.)
Patients with Duchenne muscular dystrophy cannot produce the protein known as dystrophin, which is essential in maintaining the structural integrity of muscle fibers. Over time, patients with the disorder suffer gradual muscle deterioration, which leads to paralysis and eventual death, usually by age 25.
"Conventional genetic approaches to treating the disease involve adding normal genes to compensate for the mutated genes," said Charles Gersbach, assistant professor of biomedical engineering at Duke's Pratt School of Engineering and Department of Orthopaedic Surgery and member of Duke's Institute for Genome Sciences and Policy. "However, this can cause other unforeseen problems, or the beneficial effect does not always last very long.
"Our approach actually repairs the faulty gene, which is a lot simpler," said David Ousterout, the Duke biomedical engineering graduate student in the Gersbach lab who led the work. "It finds the faulty gene, and fixes it so it can start producing a functional protein again."
The results of the Duke study were published online inMolecular Therapy, the journal of the American Society for Gene and Cell Therapy. The project was supported by the Hartwell Foundation, the March of Dimes Foundation and the National Institutes of Health.
The Duke experiments, which were carried out in cell samples from Duchenne muscular dystrophy patients, were made possible by using a new technology for building synthetic proteins known as transcription activator-like effector nucleases (TALENs), which are artificial enzymes that can be engineered to bind to and modify almost any gene sequence.
These TALENs bind to the defective gene, and can correct the mutation to create a normally functioning gene.
"There is currently no effective treatment for this disease," Gersbach said. "Patients usually are in a wheelchair by the age of ten and many die in their late teens or early twenties."
Duchenne muscular dystrophy has been extensively studied by scientists, and it is believed that more than 60 percent of patients with this type of mutation can be treated with this novel genetic approach.
"Previous studies indicate that restoring the production of dystrophin proteins will be highly functional and alleviate disease symptoms when expressed in skeletal muscle tissue," said Ousterout.
Similar approaches could be helpful in treating other genetic diseases where a few gene mutations are responsible, such as sickle cell disease, hemophilia, or other muscular dystrophies, Gersbach said.
Other members of the team were Duke's Pablo Perez-Pinera, Pratiksha Thakore, Ami Kabadi, Matthew Brown, Xiaoxia Qin, and Olivier Fedrigo. Other participants were Vincent Mouly, Universite Pierre at Marie Curie, Paris, and Jacques Tremblay, Universite Laval, Quebec.

Courtesy: http://www.sciencedaily.com/releases/2013/06/130604153946.htm